DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome))
DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome)) Uses, Dosage, Side Effects, Food Interaction and all others data.
DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome)) is under investigation in clinical trial NCT01443260 (A Study of GL-ONC1, an Oncolytic Vaccinia Virus, in Patients With Advanced Peritoneal Carcinomatosis).
| Trade Name | DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome)) |
| Generic | Olvimulogene nanivacirepvec |
| Olvimulogene nanivacirepvec Other Names | Dna (recombinant vaccinia virus strain livp clone gl-onc1), DNA (synthetic vaccinia virus oncolytic-strain GLV-1h68 (complete genome)), Olvimulogene nanivacirepvec |
| Type | |
| Groups | Investigational |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Innovators Monograph
You find simplified version here DNA (synthetic Vaccinia Virus Oncolytic-strain GLV-1h68 (complete Genome))
